theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Rheumatology

TTP   

Questions discussed in this category


Would you consider caplacizumab in a pregnant patient with iTTP?
Caplacizumab is not FDA approved in pregnant patients, but has been used safely in isolated case reports. 
1 Answer available
21198


Papers discussed in this category


British journal of haematology, 2021 Sep 29
First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy.

British journal of haematology, 2023 May 24
A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura.

British journal of haematology, 2024 Jan 02
Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab.

Cureus, 2023 Oct 16
An Interesting Case of Refractory Thrombotic Thrombocytopenic Purpura in the First Trimester of a Twin Pregnancy.

Related Topics in Rheumatology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.